Pfizer-BioNTech COVID-19 vaccine overview and safety (also known as COMIRNATY)

Details

• Corporate Authors:
  National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.
• Description:
  Updated Sept. 20, 2021
  
  NOTICE: FDA authorized the use of Pfizer-BioNTech’s COVID-19 Vaccine to be administered as boosters at least six months after completion of the primary Pfizer-BioNTech series in certain populations. The Advisory Committee on Immunization Practices is meeting on Thursday, September 23, from noon to 3pm ET to discuss a recommendation on booster shots.
  
  Cases of myocarditis and pericarditis in adolescents and young adults have been reported more often after getting the second dose than after the first dose of one of the two mRNA COVID-19 vaccines, Pfizer-BioNTech or Moderna. These reports are rare and the known and potential benefits of COVID-19 vaccination outweigh the known and potential risks, including the possible risk of myocarditis or pericarditis.
  
  
• Subjects:
  Coronavirus Infections/prevention & Control COVID-19 Vaccines COVID-19/prevention & Control Immunization, Secondary Viral Vaccines
• Document Type:
  Webpage
• Name as Subject:
  Pfizer-BioNTech COVID-19 Vaccine ; COMIRNATY
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:ec209cd10a86d867b47f05e51a7d9ae327cd0e70ea5d46ed84ad445402df06cc
• Download URL:
  https://stacks.cdc.gov/view/cdc/109956/cdc_109956_DS1.pdf
• File Type:
  [PDF - 608.40 KB ]